Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)
C. Denton (London, United Kingdom), C. Lin (South San Francisco, United States of America), J. Goldin (Los Angeles, United States of America), G. Kim (Los Angeles, United States of America), M. Kuwana (Tokyo, Japan), Y. Allanore (Paris, France), A. Batalov (Plovdiv, Bulgaria), I. Butrimiene (Vilnius, Lithuania), P. Carreira (Madrid, Spain), M. Matucci-Cerinic (Florence, Italy), O. Distler (Zurich, Switzerland), D. Martinovic Kaliterna (Split, Croatia), C. Mihai (Bucharest, Romania), M. Mogensen (Copenhagen, Denmark), M. Olesinska (Warsaw, Poland), J. Pope (London, Canada), G. Riemekasten (Berlin, Germany), T. Rodriguez-Reyne (Mexico City, Mexico), M. Santos (Almada, Portugal), J. Van Laar (Utrecht, Netherlands), H. Spotswood (Welwyn Garden City, United Kingdom), J. Siegel (South San Francisco, United States of America), A. Jahreis (South San Francisco, United States of America), D. Furst (Los Angeles, United States of America), D. Khanna (Ann Arbor, United States of America)
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Denton (London, United Kingdom), C. Lin (South San Francisco, United States of America), J. Goldin (Los Angeles, United States of America), G. Kim (Los Angeles, United States of America), M. Kuwana (Tokyo, Japan), Y. Allanore (Paris, France), A. Batalov (Plovdiv, Bulgaria), I. Butrimiene (Vilnius, Lithuania), P. Carreira (Madrid, Spain), M. Matucci-Cerinic (Florence, Italy), O. Distler (Zurich, Switzerland), D. Martinovic Kaliterna (Split, Croatia), C. Mihai (Bucharest, Romania), M. Mogensen (Copenhagen, Denmark), M. Olesinska (Warsaw, Poland), J. Pope (London, Canada), G. Riemekasten (Berlin, Germany), T. Rodriguez-Reyne (Mexico City, Mexico), M. Santos (Almada, Portugal), J. Van Laar (Utrecht, Netherlands), H. Spotswood (Welwyn Garden City, United Kingdom), J. Siegel (South San Francisco, United States of America), A. Jahreis (South San Francisco, United States of America), D. Furst (Los Angeles, United States of America), D. Khanna (Ann Arbor, United States of America). Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc). 1883
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: